Longitudinal Study of Biomarkers
| Status: | Recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any - 21 |
| Updated: | 4/21/2016 |
| Start Date: | December 2011 |
| Contact: | Margaret Nevins |
| Email: | mnevins@luriechildrens.org |
| Phone: | 312.227.4861 |
A Longitudinal Study of Biomarkers in Pediatric Patients With Central Nervous System Tumors
Biomarkers are small molecules that can be detected in the body fluids of patients; they
often correlate with the presence of a cancer. MicroRNAs and proteins are small molecules
which have recently been discovered in cells. They are known to be responsible for the
normal development of cells and when they are disrupted can contribute to the development of
cancer. Many previous studies have been done evaluating the expression of microRNAs and
proteins in normal tissues as well as a wide variety of cancers.
Recently, microRNAs and proteins from tumor cells have been detected circulating in the
blood of patients with cancer. This presents a novel opportunity to use microRNAs and
proteins in the blood as an early predictor of cancer as well as a marker of response to
therapy. Previous work in our labs have identified miRNAs and proteins in the blood and
cerebrospinal fluid (CSF) of pediatric patients with brain tumors.
To determine a longitudinal evaluation of the presence of microRNAs and proteins in the
blood, cerebrospinal fluid and urine of patients with central nervous system tumors from
diagnosis through the course of their treatment. Though the duration of active treatment
varies significantly based upon the diagnosis, patients will be followed for up to 24 months
after enrollment onto the study).
often correlate with the presence of a cancer. MicroRNAs and proteins are small molecules
which have recently been discovered in cells. They are known to be responsible for the
normal development of cells and when they are disrupted can contribute to the development of
cancer. Many previous studies have been done evaluating the expression of microRNAs and
proteins in normal tissues as well as a wide variety of cancers.
Recently, microRNAs and proteins from tumor cells have been detected circulating in the
blood of patients with cancer. This presents a novel opportunity to use microRNAs and
proteins in the blood as an early predictor of cancer as well as a marker of response to
therapy. Previous work in our labs have identified miRNAs and proteins in the blood and
cerebrospinal fluid (CSF) of pediatric patients with brain tumors.
To determine a longitudinal evaluation of the presence of microRNAs and proteins in the
blood, cerebrospinal fluid and urine of patients with central nervous system tumors from
diagnosis through the course of their treatment. Though the duration of active treatment
varies significantly based upon the diagnosis, patients will be followed for up to 24 months
after enrollment onto the study).
Inclusion Criteria:
- Patients ages 1 day to 21 years
- Patients with radiographically and/or histologically confirmed CNS tumors treated at
Children's Memorial Hospital and Lurie Children's Hospital in Chicago
- Patients must be newly diagnosed and have had no prior anticancer therapy (except
surgery) for their current diagnosis. The use of steroids is permissible.
- Patients and/or parents/legal guardians must have signed an informed consent and
assent when applicable.
Exclusion Criteria:
- Patients who have completed treatment and do not require routine blood draws and/or
lumbar punctures
- Patients who are considered too ill to participate as determined by their treating
physician
- Patients who are pregnant or lactating
We found this trial at
1
site
225 E Chicago Ave
Chicago, Illinois 60611
Chicago, Illinois 60611
(312) 227-4000
Principal Investigator: Rishi Lulla, MD
Phone: 312-227-4861
Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children
Click here to add this to my saved trials
